Aardvark Therapeutics, Inc. (AARD) Earnings Call Transcript & Summary

October 23, 2026

NASDAQ US Health Care Pharmaceuticals special 67 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day. Thank you for standing by. Welcome to the Aardvark Therapeutics Update Call. [Operator Instructions] Please advise that today's conference will be recorded. With that, I'll now turn the call over to Aardvark Therapeutics' Founder, Chief Executive Officer, Tile. Dr. Lee, please go ahead.

Tien-Li Lee

executive
#2

Good morning, everyone, and thank you for joining us today to review the efficacy and safety data from HERO, our Phase III trial of ARD-101 for the treatment of hyperphagia in patients with proto syndrome and from its open-label extension. We will also share an update on the list of FDA clinical hold. As a reminder, both studies were stopped early before reaching their plan enrollment in duration, so the efficacy results should be viewed as exploratory. Joining me on the call are Dr. Manasi Jaiman, our Chief Medical Officer; and Dr. Lynne Bird of Rady Children's Hospital and UC San Diego, who served as an investigator on the HERO trial. Manasi will walk through the HERO and open-label extension data and then moderate a fireside chat with Dr. Bird on her clinical experience with ARD-101 and the needs of patients living with PWS. I'll close with a few remarks before we open the line for questions. Before we start, we would like to remind everyone that we will be making forward-looking statements during this presentation. These statements reflect our current expectations and beliefs and are subject to risks and uncertainties that may cause actual results to differ materially. Please review the risk factors discussed in our press releases, our presentation materials and in filings with the SEC for additional information. ARD-101 is investigational and not approved. Before I turn the call over to Manasi, I want to briefly recap where the program stands. In February, we voluntarily paused enrollment in dosing in the HERO trial and its open-label extension following reversible cardiac observation that doses above the target therapeutic range in a separate healthy volunteer study. In May, the FDA placed a full clinical hold on the ARD-101 IND. In June, we terminated both trials. Since then, we have continued to work collaboratively with the FDA while completing a thorough evaluation of the totality of the unblended efficacy data and safety data from both studies. Hyperphagia is 1 of the most challenging aspects of Prader-Willi syndrome and for the patients and families looking with it, the need for effective treatments remain significant. That need has guided our work on ARD-101 from the start, and we believe the data we will share today support its continued development in PWS. As a reminder, both studies were stopped early before reaching their planned enrollment in duration, so the efficacy results should be viewed as exploratory. We will also share an update on the FDA clinical hold lift. With that, I'll turn over the call to Manasi to walk through the data.

Manasi Jaiman

executive
#3

Thank you, Tien. Good morning, everyone, and thank you for joining us today. Before I walk through the HERO and OLE results, I'd like to first provide a brief overview of the program. ARD-101 is an oral bidder taste receptor agonist that acts primarily within the gut, where it activates bitter taste receptors known as TAS2ors to trigger the release of the society hormone CCK GLP-1, a key appetite regulating hormone. These hormones then signal to the brain through the vagus nerve to dampen both hunger and appetite. We believe this mechanism is particularly well suited for patients with Prader-Willi syndrome. Hyperphagia the persistent and often overwhelming hunger that defines the disease stems from dysfunction in the hypothalamus. And by signaling through the vagus nerve, ARD-101 is designed to work around that pathway. This route also avoids the area of the brain associated with the nausea commonly seen with GLP-1 therapies. Turning our attention to Slide 3 here. We've outlined a historical overview of the ARD-101 clinical program. Our Phase II open-label trial in patients aged 1 and older was conducted in 2 parts. Part 1 evaluated doses at 200 milligrams twice daily and part 2 included dose escalation to 800 milligrams twice daily. Hyperphagia was measured by the hyperphagia questionnaire for clinical trials or HQ-CT, a caregiver reported measure of hunger-related behavior, drive and severity that is the established endpoint in Prader-Willi clinical trials. At day 28, most patients showed an average 8.5 reduction in HQ-CT scores and an approximately 9-point reduction in the 200-milligram BID group. ARD-101 was well tolerated, and these results gave us the confidence to advance into HERO, our global, randomized, placebo-controlled Phase III trial evaluating ARD-101 for hyperphagia and Prader-Willi syndrome. We made several deliberate choices in designing HERO to reflect the real-world prouder really population, we expanded eligibility to patients as young as 10 years old since hyperphagia begins in early childhood. Each patient was followed by the same caregiver and site teams throughout the trial. During HERO, there was a serious cardiac adverse event that occurred. The DSMB initially assessed event as unrelated to ARD-101 given there were no cardiac abnormalities in the previous clinical trials. The event was eventually assessed as related and it was attributed to a drug-drug interaction with pitolisant, not to ARD-101 prolonging QT on its own. Pitolisant is known to cause QT prolongation at higher plasma concentration and is metabolized by 2D6. We now know that ARD-101 is a strong CYP2D6 inhibitor at 800 milligrams BID, and thus, the AE was considered a drug-drug interaction with which the FDA concurred. In parallel, we were conducting our planned clinical pharmacology program, which included a healthy volunteer study evaluating drug-drug interactions and further characterizing ECG effects at higher doses of ARD-101. This study also provided an opportunity to better understand cardiac safety following event in HERO. The healthy volunteer study identified QRS prolongation, not QTC prolongation, which led ARD-101 to voluntarily pause all clinical trials, including HERO and its open-label extension on February 27, 2026. At the time of POS, 67 patients had enrolled in HERO and 19 entered the extension. The FDA subsequently placed the program on clinical hold in May 2026 and -- following alignment with the agency, we initiated a dedicated thorough QT study in June. The hold was officially listed last week. I'll discuss the cardiac findings in more detail when I walk through the results shortly. As a reminder, HERO stopped early, whether we paused the program in February before reaching planned enrollment, which limited its statistical power. Following the pause, we unblinded the clinical data accumulated across both trials to evaluate the totality of the efficacy and safety data and to inform our next steps for the ARD-101 program, and we are pleased to share the results with you today. Overall, in the HERO trial, we saw early and consistent efficacy signals of RG-101 activity with a well-tolerated safety profile despite early trial termination. The signal is small and early, but it follows the drug. It appears after initiation of AR101 Phase 1 ARD-101 stops and appears again when placebo patients switched to ARD-101. Again, as HERO was ended early, we can only draw directional conclusions based on the unblinded data available. What it does show is a consistent pattern. Patients improved quickly by week 2, while still on the dose escalation part of the trial. There was a strong placebo response consistent with other PWS trials. Importantly, when dosing stopped, the ARD-101 group lost its efficacy and when placebo patients switched to ARD-101 in the extension, they improved by an average of 6 additional points. on the hyperphagia score on HQ-CT9. Regarding safety, the drug was well tolerated. In Hero, as previously mentioned, there was 1 serious cardiac event related to a drug-drug interaction, which informs how we manage future studies. There are no additional cardiac SAEs or clinically significant cardiac AEs observed in HERO. And finally, from a regulatory standpoint, we are off clinical hold. On Slide 5, we provided a side-by-side safety summary. On the left is why the hold happened and healthy volunteers receiving 1,600 or 800 milligrams of ARD-101 twice daily, 3 of 31 participants had QRS widening of more than 25% from baseline. These were nonserious adverse events and reversed without treatment. On the right is the resolution. As mentioned before, we ran a TQT study to evaluate lower doses at 200 and 400 milligrams twice daily. We saw no cures prolongation and no QT prolongation in the study at either dose. In conclusion, across all studies, we saw no increases in QTC at any dose in healthy volunteer studies and no additional Q2C findings in the PWS studies. Going forward, the maximum growth will be less than 800 milligrams twice daily. Before we go into detail on the data, I'd like to provide a reminder of the HERO OLE trial design. HERO was a 12-week randomized double-blind trial. Patients were randomized 1:1 with a planned 45 per arm total 90 participants. The primary efficacy endpoint was the change in HQ-CT scores in patients starting with the HQ-CT score of 13 or higher. Patients who finished HERO could enter a 1-year open-label extension study where everyone received ARD-101. Dosing in both studies started at 200 milligrams twice daily, stepped up to 400 milligrams in week 2 and 800 milligrams from day 15 on. The titration matters. The week 2 results you will see come from the lowest doses. The next set of slides will walk you through baseline demographics. These are the patients in the efficacy analysis. On the left side are the 64 patients in HERO with a starting HQ-CT score of 13 or more, 32 per arm. Mean age was about 20, with a range of 10 to 43. The arms were well balanced on hyperphagia severity. HQ-CT scores 22.5 on ARD-101, versus 22.8% on placebo, and clinician and caregiver severity scores were similar. On the right side are the 19 patients who entered the open-label extension. Eighth from ARD-101 and 11 from placebo. They're starting HQ-CT scores and the extension are lower, which we explain on the next slides. This slide follows the same 19 patients from their HERO start to their OLE start. Both groups improved during HERO by about 6 points. So they entered the extension already better than at HERO baseline. Note that the 8 patients from the ARD-101 arm started Hero with more severe HQ-CT scores at 25 and then the 11 from placebo at 20.4%. That is why later size measure change from each patient's HERO baseline. Here is how to read these charts. -- bars below 0 mean hyperphagia improved. TAL is ARD-101 right in placebo. On the left, both groups improved during treatment. -- and those who were given ARD-101 improved more than those who are given placebo through week 8. Because the study was stopped early, many participants never reached the later visits and the number of participants contributing data decreased over time. The week 12 results are therefore too limited to support reliable interpretation. Earlier time points include near participants and provide a broader view of the enrolled population, although the early stop of the study limits conclusions across all time points. On the right is what happened when dosing stopped at the pause. On the day of pause, ARD-101 participants were 9.5 points better than baseline and placebo participants 7.8 points better. Two weeks after stopping the ARD-101 group was almost back to baseline at minus 0.3. The placebo group held most of its gain at minus 4.9% and was still present at 4 weeks. The loss after stopping was concentrated in the ARD-101 group, which is consistent with the potential drug effect. A placebo effect alone would be expected to affect both groups similarly. The numbers are small. However, we see this as a supportive of potential effect. A question we often get is how to read the placebo response in HERO. Placebo improvement is common in PWS hyperphagia trials. So this slide puts us results in that context. On the left are the HERO results for participants with baseline HQ-CT scores of 13 or higher. Both groups improved with ARD-101 participants showing modest improvement compared to placebo participants at week 2, 4 and 8. Again, because the study stopped early, fewer participants contributed to data at later visits, limiting interpretation across all time points, particularly at week 12. On the right, we show Destiny PWS, which are the results from Vicat's randomized controlled study for context. The key point is that a substantial placebo response was also observed in that trial. We believe this helps put the placebo response and hero into perspective. However, the observations are from separate clinical settings and not based on head-to-head studies. This comparison is solely for illustrative purposes and should therefore be viewed with caution as these are REM-related trials with different design and characteristics. This is the same pattern in the 19 patients who continued into the open-label extension measured from their hero baseline. On the left, look at the hatched bars. These are patients who were on placebo and hero and then switched to ARD-101. After approximately 4 weeks on drug, they improved on an average 6 more points beyond what they have achieved on placebo. On the right is what happened when the program paused and everyone stopped dosing. Both groups lost ground. Patients who have been on ARD-101 throughout went from minus 16.4% on the day of POS to minus 5.4 4 weeks later. Patients who switched from placebo went from minus 11.4% to minus 3.8%. The loss of ARD-101 effect was rapid after withdrawal of the drug, returning hosts to baseline by 4 weeks. These results are consistent with the withdrawal effect observed in ARD-101-treated patients in the week -- in the 12-week double-blind study. So in a second setting, improvement follows exposure to ARD-101. The numbers per visit are small, under 10 per group. So we treat this as supportive of potential effect only. Taken together, these findings suggest encouraging potential for ARD-101's continued development and its potential to make a meaningful difference in the lives of PWS patients. HERO showed modest numerical separation from placebo with additional support coming from the withdrawal and open-label observations. After dosing stopped, the ARD-101 group lost nearly all of its improvement within about 2 weeks, while the placebo group retained much of its game. Participants who switched from placebo to open-label ARD-101 then showed further improvement, caregiver and clinician severity ratings, CAGIS and CGIS followed a similar pattern. Improvement after starting ARD-101, followed by worsening after stopping it provides a consistent signal of potential treatment effect. Although these findings are not definitive, we believe they offer an encouraging rationale for further evaluation. For completeness, we collected and reviewed all prespecified assessments, lipids, hemoglobin A1c, weight, body composition, vital signs and ECG showed no meaningful differences from placebo participants. Longer treatment and follow-up may be needed to assess potential metabolic effects, particularly given the early study stop. Plasma concentrations were low, consistent with limited systemic exposure and ARD-101's intended action primarily at target receptors in the gut. In this space, tolerability is as important as efficacy. Given the nature of the disease, PWS patients may be treated for many years. Shown here are the most common adverse events. These were infrequent and balanced across arms. None occurred in more than 9% of patients and rates were similar between ARD-101 and placebo. Diarrhea and nasal congestion were the most frequent each at 3 patients per arm. Across both studies, ARD-101 was generally well tolerated. In HERO, adverse events occurred in 52% of ARD-101 patients and 50% on placebo. -- mostly mild to moderate. Fewer ARD-101 patients had a related event than placebo patients, 15% versus 21%. As mentioned previously, there was 1 serious cardiac event at 800 milligrams twice daily attributed to a drug-drug interaction with pitolisant. There were no other cardiac adverse events. In the extension, there were no serious events. All 8 related events occurred in patients newly starting ARD-101 and 7 of 8 were mild. Patients who had already been on ARD-101 in Hero had no related events. We believe this is supportive of promising tolerability over time. I'd now like to turn to our fireside discussion with Dr. Lynne Bird. Dr. Bird is a rare disease specialist and clinical geneticist at Rady Children's Hospital and Professor of Clinical Pediatrics at UC San Diego. She is a Medical Director of Rady Children's multidisciplinary Prader-Willi Syndrome Clinic and Co-Founder of the Rady Children's Down syndrome Center. Dr. Bird has spent much of her career caring for individuals with Prader-Willi syndrome and their families. And she served as an investigator on the HERO trial. She brings a perspective on both the day-to-day realities of living with hyperphagia and what it means to evaluate a potential new treatment in the clinic. Dr. Bird, thank you for joining us today. We're honored to have you here.

Lynne Bird

executive
#4

Manasi, it's nice to speak with you again.

Manasi Jaiman

executive
#5

Yes. Hello, Dr. Bird. Thank you again for joining. Let's get started with this. So could you tell us a little bit about your background and how you came to focus on Prader-Willi syndrome.

Lynne Bird

executive
#6

Sure. I'm a clinical geneticist. I've been in practice for 32 years. I mostly see children who have first effects or neurodevelopmental problems that are seeking a diagnosis. And in 2005, I believe it was -- I was asked to start a Prader-Willi syndrome clinic because the 1 at UC Irvine was closing due to the retirement of the director -- and so I do. And we've been in operation ever since then, and we see about we follow 40 to 50 patients every year, seeing them about once or twice a year, depending on their needs.

Manasi Jaiman

executive
#7

Wonderful. Thank you so much. And I know the patients are going to be so grateful because of the fact that there's such a few clinics across the country. So because of your vast experience and your background, when you think about Prader-Willi syndrome now, what do you think is the greatest unmet need?

Lynne Bird

executive
#8

Well, I would have to say it still is hyperphagia. That's been the answer for decades now. And I think it's still the main issue, which makes life just very difficult for families. The children basically feel like they're starving and are so focused and preoccupied with food and are -- it's very difficult to do the usual things that we do in our society, which is to get together and have a meal with friends or family because the children don't understand why food is coming for another table in the restaurant and not for them, and they have a meltdown. And it's just -- it's very difficult to compound the hyperphagia the individuals with Prader-Willi syndrome have slower metabolism. And so they need fewer calories than a typical person. So the combination of having an increased drive for food an increased sensation of hunger and not being able to eat nearly as much as a typical person just is an incredibly difficult combination for families.

Manasi Jaiman

executive
#9

I'm always amazed with the burden that comes with this disease and the fact that families and participants continue to support clinical trials, and we are forever grateful to them and including the sites as well. And I always think about from the perspective of the families, the patients but also as an investigator, -- why did you choose to participate as an investigator?

Lynne Bird

executive
#10

Well, I mean, we really don't have any effective treatment for hyperphagia. It's we call it a treatment, but it's really not when we say secure the food supply. So it's like lock the food and keep control over the diet. -- that's not really a treatment. It doesn't really affect the symptom. It just manages the symptom. And I was fortunate enough in 2016 to be to participate in a Prader-Willi syndrome clinical trial. And that was my entry into the entire clinical trial world. And I think it's the path forward to finding treatment. So I'm committed and I know many of my colleagues who see prouder patients are also equally committed -- and more importantly, the families are super engaged. This is a highly sophisticated and engaged population. They are really asking for and wanting to participate in clinical trials, we've never had a struggle with enrollment.

Manasi Jaiman

executive
#11

That's great. And then again, like I said, I am always so grateful for these families and the participants. And I have learned quite a lot from just them, not just about the disease, but how do you even run a clinical trial effectively based on what their needs are. Just because as you described, their day-to-day burden is so high. And the fact that they are able to participate in these clinical trials is always so amazing to me. And 1 thing we're always kind of thinking about for them and how to decrease the burden when they participate, but also -- what is it that makes participation easier, what makes their lives easier when we think about therapy. So what are some of the factors, including ease of administration, how do they affect part of really families and participants?

Lynne Bird

executive
#12

Yes. So this is a group of patients who in the modern era have grown up with daily growth hormone injections. So they don't necessarily shy away from something that has a tougher route of administration. But certainly, an oral drug is going to be far easier, far less dramatic and especially something that only has to be given twice a day makes it nice that you -- well, that you don't have to synchronize it with meals and that you don't have to worry about a midday dose where you're going to have to a range for it to be given to the child by the nurse at school. So twice a day dosing is very feasible, very doable.

Manasi Jaiman

executive
#13

Great. Great. Now again, now with your experience that you have in your background, -- and especially as you've seen clinical trials develop over time, how they've been run, the data that's been produced, even with the recent progress in the field, -- where do you see the largest remaining unmet need for these patients and families? Because for me, as a pediatric endocrinologist, I think about how many more tools can we get these families. Where do you think we are now in this space specifically and especially for hyperphagia?

Lynne Bird

executive
#14

Well, as you know, there is a drug approved for hyperphagia. It certainly doesn't work for everybody, and there are patients that are -- that's probably contraindicated in because of other health morbidities that they have. And in my experience, it takes the edge off, but it certainly isn't miraculous in terms of ceasing entirely hyperphagia. For those that it works for, it obviously makes life easier because there's a little less focus on food, and it's a little easier to redirect patients after they're asking for food. But it's certainly doesn't allow families to just throw caution to the wind, unlock the cabinets and have it be a free for all. So there's still a huge amount of burden that comes with making sure a person is food secure and not having unrestricted access, which can be a lethal complication patients with unrestricted access to food have eaten to the point of stomach rupture that's well described in Prader-Willi syndrome. So the new drug doesn't take away the need for families to continue to do all the hard work. It just makes the hard work a little easier. So obviously, we need more things in our tool chest for hyperphagia, hyperphagia does drive a lot, not all, but a lot of the behavior that we see in Prader-Willi syndrome. There's a tremendous amount of anxiety and perseveration and a lot of aspects of behavior get better when patients are provided food security and when you take the edge off with a drug like VCA.

Manasi Jaiman

executive
#15

We need more. We do. We do. And this is why we continue to strive forward. We're excited to be able to share the data today. We are so grateful that you were part of this journey and continue to be and we're really grateful for the community advocacy groups, the participants, the families. And these insights are so invaluable to continue to improve how we run clinical trials and continue to strive towards bringing new therapies to patients. So Dr. Byrd, thank you so much for sharing your insights today and for your continued commitment to us and to the PWS community. With that, I'm going to turn this over back to Tim for some closing remarks. But again, thank you so much, Dr. Byrd.

Lynne Bird

executive
#16

Pleasure to be here.

Tien-Li Lee

executive
#17

Thank you, Manasi and Dr. Bird. Hyperphagia remains 1 of the most difficult aspects of carriage patients and their families, their constant hunger shapes nearly every part of their daily life. And we believe there is still a minuet need for additional treatment options that can meaningfully reduce it. The data [indiscernible] through today are exploratory, but we believe they are directionally consistent with what we saw in Phase II, and it give us confidence in the continued development of ARD-101 for PWS. Our next step is to request the meeting with the FDA to align on the design of a Phase III study intended to support a future marketing application. We will continue to work closely with the AUC as we move forward. Before we open the line for questions, I want to thank the patients, families, caregivers and investigators who took part of the HERO and its extension as well as the PWS advocacy community whose partnership has been essential to this work. With that, operator, please open the line for questions.

Operator

operator
#18

[Operator Instructions] And our first question comes from the line of Josh Summer of Cantor Fistel.

Joshua Schimmer

analyst
#19

I have 2 for the management team and 1 for Dr. Bird. So first, just trying to understand for the chart that's on the left side of Slide 11. What is the difference between the week 12 and that the study week 0 in the open-label period. I thought patients would just roll it into the open label, so 12 and 0 should be the same, but they don't look the same, and it actually doesn't look like there's a difference between the 2 groups at that 0 time week. That's number one. Number two, how do you plan to incorporate ECG monitoring going forward? And then through commercialization potentially of 101, including with REMS? And then for Dr. Bird, is there a tolerable QRS widening signal that you think would be acceptable for the community if indeed there is an efficacious dose to be found here? Or is that not something that is tolerable at all for patients?

Tien-Li Lee

executive
#20

Manasi, you can take those questions.

Manasi Jaiman

executive
#21

Great. Yes. Josh. So -- great question. So let's start with the first question you had. So Slide 11, specifically in the transition from week 12 to open-label -- so most participants -- remember, these are small ends. So even with 1 having even a minor gap between week 12 and open label can shift what that looks like. But most participants had the same day transition visit from week 12 to open label, but not all. And so that's where you're seeing the difference. And again, because at each visit, if there was even a small gap, we have them redo the HQ-CT9 to really capture their baseline before entering the part of the study, that's where that discrepancy comes from. And it could be for multiple reasons, as you know, in clinical trials, where participants, they decide on that day that they want to wait a couple of days before they go into open-label extension. But I will say that 100% of those that were able to go into open-label extension chose to going up open label extension. So that was very encouraging for us. But certainly, if there's even a 1 or 2-day gap, we have to redo the HQ-CT mine. The second part of your question is cardiac monitoring. So in terms of cardiac monitoring for future trials, we certainly learned quite a bit from our HERO and open-label extension trial. And yes, there will be more cardiac monitoring as we move forward in clinical trials and especially in our development to ensure patient safety because that is #1, 2 and 3 for us to ensure that we're capturing these things. I think what's encouraging for us is that TQT study we did do at these lower doses now and that we had no further signals, especially in the QRS prolongation piece. And so for us, it will just be another safety measure as we move forward. In terms of the label or commercial -- post commercialization, cardiac monitoring, we'll learn what we do with our next clinical trial, and that will determine what is required post commercialization. And I think the last question is for you, Dr. Bird.

Lynne Bird

executive
#22

Sure. Obviously, you know that I'm not a cardiologist. I think that a little bit of QRS widening that was not associated with any symptoms at all, would likely be considered tolerable by the population, whether it would be considered tolerable by the FDA is another matter. But I -- my understanding is none of the healthy volunteers who exhibited the QRS widening had any symptoms that purely electrical finding and not 1 that we expect to see with the revised protocol at lower doses.

Operator

operator
#23

Our next question comes from the line of Chris Raymond of Raymond James.

Christopher Raymond

analyst
#24

Just 2 questions maybe. I guess first on safety. I think there's -- there are a few psychiatric meds that are used in PWS that are metabolized by CYP2D6. Have you guys evaluated whether the interaction that you saw with pitolisant could potentially extend to other concomitant meds, like antipsychotics, antidepressants. Just maybe talk about how you're thinking about that with future trial eligibility and then just noticing the slides, the last slide in the deck that you guys have shows a pretty impressive average from baseline, I think it's almost 12 HQ-CT reduction. How do you -- I know that's a little bit messy, right, because you've got some folks that started on placebo, et cetera, but maybe put that into the context of what we saw with the HERO and blinding.

Manasi Jaiman

executive
#25

Sure, Chris. Yes. Thank you, Tan, and I'll take this. So let's start with the first question you had for -- so I want to caution so when we did the drug-drug interaction, for CYP2D6. That's when we learned at the higher dose, which is 800 milligrams twice daily, that we were a strong inhibitor. Now yes, there are other medications that are CYP2D substrates. And there is a range between being potent versus being mild. Now what we know at this higher dose that we are a strong inhibitor. What we don't know is how strong of an inhibitor we are at these lower doses. And so that would be the next step for us is to learn that, which would directly impact what we would include or exclude from our clinical trials. I think we are iterating and we've learned quite a bit and we did have participants on these antipsychotics in our clinical trial that did not have this outcome. And this again was at 800 milligrams twice daily. So as we propose going at lower doses moving forward, I think we're going to learn more and hopefully not have the same requirements, but there's more to come. And then in terms of that second question for the open-label data that you've seen in that last slide, and especially that falls. So certainly, it's encouraging. So if you recall, our Phase II data, especially at the 200 milligrams twice daily, it was open label as well, and we had approximately a 9-point drop in hyperphagia as well. And so this is more a comparison with that data. We are encouraged with this and in terms of the HERO, HERO is an RCT, but we're looking at from baseline all the way going into open label to see that kind of drop even outside of having placebo response. I think for us, directionally, that's very important to continue to see on top of the withdrawal data, I think that's what allowed us to present to date and have conviction to move this program forward.

Operator

operator
#26

Our next question comes from the line of Leland Gershell of Oppenheimer.

Leland Gershell

analyst
#27

Great. and taking questions. Just wondering, and would love to hear from both the company and Dr. Berg on this with respect to the changes seen between the drug and the placebo group, both during the -- what we have from the controlled portion and also the jump to the OLE. Just if I recall correctly in the at studies, patients who had a worse baseline HQ-CT score tended to have greater improvement during that those studies or that study. I'm not sure if that was a resolve to be drug-related or maybe just return to the mean on -- without -- in the absence of a drug effect. But just wondering how that may weigh in your minds as you look at these data from both the controlled and the open label portion.

Tien-Li Lee

executive
#28

Manasi, also, are you comfortable taking that one?

Manasi Jaiman

executive
#29

So can you clarify that question a little bit for me?

Leland Gershell

analyst
#30

Sure. So yes, in the Vykat studies, I believe it was shown that those patients who had higher HQ-CT at baseline tended to improve more versus patients who had had lower HQ-CT scores at baseline. So I'm just wondering, given that there was a difference, if you look at the baseline panel on Slide 8, just between ARD-101and placebo, there's the differences, both in the HERO and the between those 2. And I'm just wondering how those may weigh either in favor or not in terms of an actual drug effect, it's small numbers, but just how those may way in terms of the potential for ARD-101 here?

Manasi Jaiman

executive
#31

Okay. Great. Great question. Okay. I understand that. So in terms of the baseline, yes, there was a difference. And I think when we -- that's why, a, you have a cutoff in the inclusion criteria for a introducing participants in this trial. So our ITT population was greater than or equal to 13 against standard in the PWS inclusion criteria for hyperphagia at baseline. And so that's considered moderate hyperphagia. And so even with this difference, it's how you look at it from baseline. So we actually did change from their own baseline versus the average change based on cumulative baseline or aggregate data. So I think for us, it was really looking at the data change perspective. Now again, we couldn't run any statistical models here, obviously, because it was a truncated trial. So at this point, we have to look for change from baseline and how we ran the modeling based on just that. I hope that answers your question.

Leland Gershell

analyst
#32

That's helpful. And I also wanted to ask with respect to these data, I know it's a partial data set from a trial that was plus early, but any plans for either publication or presentation of medical meetings?

Manasi Jaiman

executive
#33

Yes. Great question. And I think this is valuable data. I think we're working through a publication strategy and what that would entail, but we do hope to deliver something in the future.

Operator

operator
#34

Our next question comes from the line of Catherine Novack of Jones.

Catherine Novack

analyst
#35

Is Dr. Bird still available for questions or I did have 1 on Vykat and safety?

Manasi Jaiman

executive
#36

Dr. Bird...

Lynne Bird

executive
#37

I'm still on the line. Yes.

Catherine Novack

analyst
#38

Great. So I guess, I would just be curious to understand your thoughts on what are you hearing from the rest of the community in terms of growing potential safety signals coming from Vykat and beat thoughts on requirements for say, for more and potentially more efficacious treatment?

Lynne Bird

executive
#39

Well, we clearly need a more SKS treatment. And there -- the safety issues that have come up, I don't think there's any necessarily any surprises here. I think that whenever you have inclusion criteria that include a fairly healthy and regulated population at the outset, then when the drug gets opened up and is used in the real world, it may be applied to patients who were not ideal candidates. And certainly, there's been some further guidance given out as to how maybe we should monitor patients as they are titrating up on Vykat. So as I said, I don't think it's the drug for everybody. because some patients with substantial comorbidities may not be candidates for that drug. So we, for sure, need more, and we, for sure, need better options out there.

Catherine Novack

analyst
#40

Got it. And then this 1 is for Aardvark management. I guess, can you clarify the use of concomitant medication for PWS in the HERO trial, to my understanding that the Telesat can impact HQ-CT -- so what were the requirements to be stable on medication prior to enrollment? Was this something that was meant to be strapped stratified for randomization?

Manasi Jaiman

executive
#41

Sure. Great question. I can take that Tan. So in terms of concomitant medications, as with all clinical trials, they do have to be on stable therapy entering the trial. So for us, it was standard, which is approximately 3 months of stable therapy, no changes in chronic medications. And that would be required regardless of what medication they come in with as long as it complies with our inclusion/exclusion criteria.

Operator

operator
#42

Our next question comes from the line of Casino Ma of Bank of America.

Unknown Analyst

analyst
#43

Okay. Great. So now that you have this hold lifted you've talked about requesting a meeting with FDA to align on Phase III design. What is the remaining gating factor between now and when you have the meeting? Like is there any additional information you need to collect and when would we get clarity on what the final Phase III trial design would be? And then also, as part of that, given Vykat is approved, how would you think about ideally handling that in the Phase III program? Would you allow patients to be on background by CAD XR? Would you require them to be off of it? What are some suggestions do you think you'd be giving FDA? And what do you think the pushback would be?

Manasi Jaiman

executive
#44

Okay. Great. Tien so I can take this question. So in terms of our next iteration of the trial, so we haven't disclosed that yet. We are working through alignment with the FDA and hope to bring you more updates, so as much as I can answer it there. But in terms of Vykat, I will also remind you that Vykat was approved while we were actively enrolling participants in our Phase HERO and open-label trial. And so we already have experience with that. I will say that when we are running clinical trials, what we really want to do to have a clear understanding of your own therapy is really to limit other therapies that could interfere with understanding signals. And so even within our HERO and open label, they were not allowed to be on Vykat during the clinical trial, so we can have pure results, and there would be no variability or bias introduced from other therapies. That can -- that are therapy specifically for hyperphagia. And so I don't see that changing for our next clinical trial because, again, we want to have clear understanding of our own drug. That being said, you do not think our drug is mutually exclusive from Vykat for in the future. But right now, for a clinical trial, we would want to limit any interference with other drugs. -- specifically for hyperphagia. And in terms of what the FDA may align with on that, this isn't actually a typical for clinical trials because if you are setting a drug in hyperphagia, having another drug that could limit your understanding of it, usually is not something that most clinical trials will have.

Unknown Analyst

analyst
#45

Okay. And then a quick follow-up. There are other companies that are trying to pursue Prader-Willi with different mechanisms of action. So in terms of how long it could take to recruit a trial, maybe Dr. Byrd can also opine. Do you have a sense of whenever it is that you start to study, how many sites you might need? And how long it could take to recruit just given that there might be others also try.

Manasi Jaiman

executive
#46

So Dr. Bird, I can answer the first part, and then it'd be really great to get your perspective on it as an investigator. So I will say this that I am very encouraged with the space. We are so thrilled to know that and especially as the pediatric endocrinologists that more therapies are being worked on for these patients who desperately still need it because of the continued unmet need with addressing hyperphagia. It's a great news for all of us. In terms of recruitment, though, I will also say that even while we were undergoing or HERO and open-label extension with an approved product, we were still doing fairly well with recruitment and how we were engaged globally. And I don't see that changing. I think that there is still such space, as Dr. Bird mentioned earlier, there's still such a high unmet need. I think continued development, I think there's still going to be continued participation. And I think that the other really key piece in the space, at least as an endocrinologist, but also as someone at this company is that continued engagement with the families, the participants, the advocacy group, we have such good support from them. I don't see that changing. We've been and we've always put patient safety first. And so I feel that we are going to be okay in terms of the recruitment piece. But Lynne, I'd love to hear your take.

Lynne Bird

executive
#47

Well, I was just e-mailed by a family who's listening to the webinar, who said, we're in. So hugely highly engaged. I know highly engaged community. And as I said, we've never had problems with enrollment. Obviously, now VICATs out there, and that's probably going to be an exclusionary criteria. So it may narrow the pool, but there are certainly plenty of families out there who are still interested in research, still committed to the process and for 1 reason or another, not on Vykat, not interested in Vykat. So I don't foresee big struggles with enrollment.

Operator

operator
#48

Our next question comes from the line of Brian Avinor RBC Capital Markets.

Brian Abrahams

analyst
#49

Thanks for the very, very clear and detailed presentation. It's super helpful. One question on data and then 1 question on path forward. Maybe just on the data and looking at Slide 10 at the 12-week mark. I'm just curious, just if you kind of look at those 24 patients who kind of made it through the 12-week dosing period, can you talk a little bit about how their HQ-CT scores tracked over time? I guess I'm asking because I'm wondering if there could be the potential for some waning effect as patients get out to 12 weeks, or if that -- that snapshot of those particular 24 patients just represented a group that maybe was not quite as responsive to ARD-101. And then secondarily, just on the go-forward path, I know it's still being worked out with the FDA. But I guess I'm curious, do you have a sense of what dose 200 or 400 you might pursue, might you pursue an -- and if you've planned for, I guess, the similar effect size as you're seeing signals of here, how large would the test need to be in order to be adequately powered for sensical significance?

Manasi Jaiman

executive
#50

Great. So Tien, I can take that and please add if you need to. So the week 12 data, A couple of things to think about. And as I mentioned in the webcast as well, is that this stopped early. So when you look at the earlier weeks, that's where the bulk of the patients, and I think that's a broader representation of the population that entered the clinical trial, but certainly didn't go all the way through because we stopped the study very quickly. So on February 27, where the patients were as they are in the trial, that's where they stopped. And so the bulk actually didn't even make it all the way through. That being said, even at week 12, we actually, as you would have, and we have 3 participants, as you can see in there that actually didn't -- well, actually, we didn't show you this, but the 3 participants didn't complete the study because they -- we have 3 that we had actually a very low dropout rate of under 5%. But we also had -- that were on ARD-101 that make it all the way through and then compile that on top of the fact that we just had a truncated trial where most participants didn't make it through. It's really hard to interpret the week 12. And there are -- there is also a nuance in the H2CT9. It's a 2-week look back as well. So you really want to look at directionality over a long period of time, not just 1 time point. And so which is why having a full trial, a completed trial, open-label data for a long period of time is very important. And for us, when we looked at the data ourselves, it was really looking at directionality. And answering that 1 question, are we seeing something -- are we seeing loss of effect and both answers are yes, and should we continue to develop this program and the answer was yes for that. And in terms of your second part of that question in terms of path forward, I think that for us, in terms of dosing, I will tell you the data on hand. Our thorough QT study we did was at lower doses. What the trial design will look like, how it will be powered will be to term based on our clinical trial design that we are still pending alignment with the FDA.

Operator

operator
#51

Our next question comes from the line of Kelcy Loser of William Blair.

Unknown Analyst

analyst
#52

This is Kelsey on for Andy from William Blair. So perhaps kind of related to the prior question, we were curious if you're seeing on observed sort of dose exposure relationship here and if that's a linear relationship or not. And perhaps if that translates to the efficacy you're seeing by dose in this sort of initial look at the data? And how might that inform kind of your approach to the Phase III? Will you be progressing directly into one? Or do you anticipate doing maybe additional dose ranging work?

Manasi Jaiman

executive
#53

Great. So I will say there -- so far, there's no clear dose response or exposure -- it seems to be similar at week 2 and at week 4 and week 2, if you recall, we're at the lower doses. And then the other pieces are Phase II showed a 9-point reduction at the 200-milligram price daily dose. So we do have data to support these lower doses. But again, as I mentioned, there are no clear dose response.

Tien-Li Lee

executive
#54

And I might add a little bit based on our -- basically, when we were going into Phase II, the reason why we chose 200 milligrams at that time was because we thought that was going to be more than sufficient based on our understanding of receptor engagement for the receptors that we're targeting and the reason we moved up to 800 because at the time, we had talked at our dose ceiling was effectively a lot higher than it might be limited by now, and that was just to accommodate rise potential for dilution effect. But based on first principles, we actually had strong for 200 milligrams, which is why you see other Phase II studies we're also targeting that dose. So that's why we didn't expect to see a dose response from the users that we had a reflector Phase II, even though we explored higher doses, the low dose proacted better than that high dose creep in our Phase II. So I hope that answers your question.

Unknown Analyst

analyst
#55

Yes. Very helpful. And if I could sneak in another quick one. Following this update, we were just curious how this might impact your plans for ARD-201. And kind of what you view as key development or decision points for that program going forward?

Tien-Li Lee

executive
#56

I have announced, go ahead, Manasi.

Manasi Jaiman

executive
#57

No, I think we're going to say the same thing. We haven't really disclosed our development plans moving beyond PWS. Our focus remains on the Prader-Willi community at this time.

Operator

operator
#58

Our next question comes from the line of Michael Ulz from Morgan Stanley.

Michael Ulz

analyst
#59

Maybe just a follow-up on some of the earlier questions related to the thoughts on the Phase III trial design. Just curious if you're considering randomized withdrawal study. And then when you meet with the FDA, are there specific areas where you're seeking feedback.

Manasi Jaiman

executive
#60

Great. So Mike, so I think in terms of our Phase III trial design, it is encouraging that there is an approved pathway for an RWD, that being said, we are still pending alignment with the FDA on what our trial design will look like.

Operator

operator
#61

Our next question comes from the line of William Wood of Bali Securities.

William Wood

analyst
#62

When we're just thinking about the patients who received the drug in terms of your secondary influence that you looked at, you compare those 2 from placebo. But I was curious when specifically just looking at the active drugs and separating us apart. Could you speak to any changes in body weight or other hyperphagia related endpoints that you may have seen so that will support the efficacy that you already saw. And then thinking about sort of the next steps into Phase III, is it -- is it to say that the FDA would view HERO as contributing to the registrational package? Or do you think that there would need to be an additional trial after that also after your next Phase III?

Manasi Jaiman

executive
#63

So I think I missed the first part, a little broken up, but I'll start with the second part, and maybe you can reiterate on the first one. But in terms of our current data, certainly, it's a truncated trial. But it is still supportive. We have some data from a safety standpoint. We have some supportive data. But again, we have to wait until we kind of work things out with the FDA and alignment on that next trial and how it could be used for registration. So hopefully, more to come soon on that piece. And then can you circle back on that first part of that question, please?

William Wood

analyst
#64

Sure. Yes. Just thinking about the patients who did receive drug, I was curious what the changes in your secondary endpoints were not specifically related to placebo, but just did they align with the HCT that we saw specifically thinking about body weight and/or other hyperphagia-related end points?

Manasi Jaiman

executive
#65

Yes. So okay, I understand. So in terms of the secondary, so the secondary endpoints were actually other caregiver assessments, and they cared to renclinician assessments and they did follow a similar trend with the HQCT. Now with our exploratory measures in that 1 of the slides that I had presented, again, because it's truncated in a lot of these metabolic parameters and even BMI take time for change. And so because we had such a truncated trial, we didn't see -- we saw minimal changes. I do think that had we run a longer lengthier period, we would probably have had a bit more dynamic results to share today, but we are absolutely following this again in our next trial. And hopefully, we'll have more robust results to share.

Operator

operator
#66

Our next question comes from the line of Ran Sabarad of AC Windlin.

Unknown Analyst

analyst
#67

I was just wondering when you might have additional clarity regarding the drug-drug interaction profile of ARD-101? And specifically at which doses there might not be any meaningful risk of such interactions. If you can give us a sense of when you anticipate being able to provide us with further clarity on that front. And then a question for Dr. Bird. You had mentioned that there remains a significant unmet need with respect to addressing hyperphagia in Prader-Willi syndrome patients. And I was just wondering if you could maybe characterize that a little bit more granularly for us in the context of the availability of Vykat XR in terms of how you would gauge -- how you would rate the overall efficacy and risk benefit profile of that drug. Obviously, you made comments before about the degree to which there are side effects with that agent. The risk of significant adverse events but just give us a greater sense of the extent to which you believe that the PWS community is currently being served by Vykat XR and what the nature of the unmet medical need is as well as the specific characteristics of any patient subpopulation. For example, those with poor glycemic control within the Prader-Willi syndrome population as a whole, who might be especially unlikely to be considered candidates for Vykat XR and whether you would deem these to be particularly well suited for treatment with a drug like ARD-101.

Lynne Bird

executive
#68

So it's a lot to -- go ahead, Manasi.

Manasi Jaiman

executive
#69

No, no, I think go ahead and answer, and then I can go back because I think yours was length here.

Lynne Bird

executive
#70

Yes. So certainly, there are patients who may -- ICAP may not be a good drug a good choice for them because of other comorbidities that they have. But even those who are put on by cat, not everybody responds. And as I said, even those who respond, it doesn't -- it's not like a complete tapping of the appetite entirely. And it just sort of takes the edge off. So something that would allow families to go to a family reunion and not have to worry about keeping their eyes on their kid every single second because they're spot out would really be helpful. I think it's too early to know whether this drug is going to be a better choice for individuals of credit release in them or not. But it's very clear that we need more than what we have.

Manasi Jaiman

executive
#71

Great. And then I can address that first part of the question, just clarity on the DDI. So what I will say is that our information right now based on our DDI trial that we ran in healthy volunteers, at 800 milligrams twice daily is that we are a strong CYP2D6 inhibitor. We still have to do a trial that will look at lower doses at lower exposures. But hopefully, we will have that to share with you at a future time. But again, we're still -- I think we have some information on hand, and we'll continue to iterate to understand what this could look like at lower exposures.

Unknown Analyst

analyst
#72

So just to clarify what you are

Manasi Jaiman

executive
#73

Sorry. I think you dropped. Just to clarify.

Operator

operator
#74

It looks like disconnected. Thank you. This concludes the question-and-answer session. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Aardvark Therapeutics, Inc. transcript — plus 261,000+ transcripts from 13,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Aardvark Therapeutics, Inc. earnings transcripts and 261,000+ others is available through the EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Aardvark Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.